Related Experiment Video
Updated: Apr 9, 2026
Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock
Published on: August 16, 2021
Generalizability of Landmark Temporary MCS Device Trials: Insights From the CSWG Registry
Song Li1, Claudius Mahr1, Rachna Kataria2
1Institute for Advanced Cardiac Care, Medical City Healthcare, Dallas, Texas, USA.
Insights
Few cardiogenic shock (CS) patients meet criteria for landmark trials like DanGer Shock. This highlights an evidence gap for real-world temporary mechanical circulatory support (tMCS) use in CS patients.
Area of Science:
- Cardiology
- Clinical Trials
- Medical Devices
Background:
- Landmark trials (DanGer Shock, IABP-SHOCK II, ECLS-SHOCK) inform cardiogenic shock (CS) management using temporary mechanical circulatory support (tMCS).
- Strict trial enrollment criteria may limit the generalizability of findings to real-world patient populations.
- A significant evidence gap exists for CS patients not meeting these specific trial criteria.
Purpose of the Study:
- To assess the overlap between patients in the CS Working Group registry and the eligibility criteria of three key CS trials.
- To compare baseline characteristics and tMCS device utilization between trial-eligible and trial-ineligible CS patients.
Main Methods:
- Retrospective analysis of CS patients from the CS Working Group registry (2020-2024).
- Application of trial-specific enrollment criteria (DanGer Shock, IABP-SHOCK II, ECLS-SHOCK) to registry patients.
- Comparison of demographics, clinical data, and tMCS device usage patterns.
Main Results:
- A small fraction of registry patients met all criteria: 19.3% (DanGer Shock), 28.4% (IABP-SHOCK II), 23.6% (ECLS-SHOCK).
- Hypotension and elevated lactate levels were the most restrictive criteria.
- Trial-eligible patients exhibited more severe CS and end-organ damage.
- Real-world tMCS device use often deviated from trial assignments; only 20% of DanGer-like patients received Impella CP first.
Conclusions:
- Patients meeting landmark CS trial criteria represent a high-risk, minority subset of the real-world CS population.
- A substantial evidence gap exists for the majority of CS patients receiving tMCS in clinical practice.
- Improved registry enrollment and innovative analyses are needed to bridge the gap between trial evidence and real-world application.
Background:
Landmark randomized controlled trials like DanGer Shock, IABP-SHOCK II, and ECLS-SHOCK guide infarct-related cardiogenic shock (CS) management with temporary mechanical circulatory support (tMCS), but strict enrollment criteria may limit real-world applicability.
Objectives:
The objective of the study was to evaluate the eligibility overlap of patients from these three key CS trials with the contemporary CS Working Group registry.
Methods:
In this retrospective analysis, CS patients enrolled between 2020 and 2024 in the CS Working Group registry were assessed. Using trial-specific enrollment criteria (DanGer Shock, IABP-SHOCK II, and ECLS-SHOCK), subsets of patients meeting these criteria were identified. We compared baseline characteristics and usage patterns of tMCS devices among trial-eligible and trial-ineligible patients.
Results:
Only a small proportion of registry patients met all the key enrollment criteria: 19.3% (DanGer Shock), 28.4% (IABP-SHOCK II), and 23.6% (ECLS-SHOCK). Hypotension and elevated lactate thresholds were the most restrictive criteria across trials. Trial-eligible patients had more severe CS and end-organ damage than ineligible patients. Actual device use in real-world practice differed markedly from trial assignments; notably, only 20% of DanGer-like patients received Impella CP as their first device.
Conclusions:
Patients meeting the landmark CS trial criteria represent a small, high-risk subset of the real-world CS population, highlighting a substantial evidence gap for the majority of CS patients receiving tMCS in clinical practice. Enhancing registry enrollment of specific CS subsets and adopting innovative analytic strategies could bridge gaps between randomized controlled trials findings and real-world applicability.
